Tradestie Institutional Equity Comparison Engine

GRML vs IBO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

IBO Overall Edge

IBO Captures Institutional Edge (3โ€“0 Pillars ยท 7โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Impact BioMedical, Inc. (IBO) driven by superior Valuation, Growth & Margin, Momentum & Technical. Fundamentally, GRML trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus IBO at N/M Forward P/E and -12621.0% operating margin (+16.7% YoY). In options structure, GRML sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against IBO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner IBO
GRML N/M vs IBO N/M Fwd P/E
Growth & Margin Winner IBO
Op Margin N/A vs -12621.0% ยท YoY N/A vs +16.7%
Momentum & Technical Winner IBO
1Y +650.0% vs +872.5% ยท 52W Pos 19% vs 68%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
GRML US Equity
GRML
Institutional Equity
$3.51
-2.77% 1D
Market Cap N/A
1M Return -41.5%
1Y Return +650.0%
Forward P/E N/M
Unified AI Score
56.8 / 100 HOLD
Tech 60.0 Fund 57.0 Flow 50.0 Mom 60.0
IBO NYSE American
Impact BioMedical, Inc.
Pharmaceutical Preparations
$4.96
-3.5% 1D
Market Cap $41.2M
1M Return +85.07%
1Y Return +872.55%
Forward P/E N/M
Unified AI Score
36.8 / 100 SELL
Tech 15.0 Fund 32.0 Flow 50.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: GRML +650.0% IBO +872.55% Spread: +135.56 pp (IBO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
GRML TTM Op. Margin: N/A IBO TTM Op. Margin: -12621.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GRML vs IBO. Trailing 12-month operating profitability (GRML N/A vs IBO -12621.0%) and valuation multiples (GRML N/M vs IBO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: GRML (2) vs IBO (7)
Institutional Metric GRML IBO Criterion Row Winner
Market Capitalization Scale N/A $41.2M Larger Scale IBO
Trailing P/E Ratio Valuation N/M 0.4x Lower Multiple IBO
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A +16.7% Higher Growth IBO
Operating Margin (TTM) Profitability N/A -12621.0% Higher Margin IBO
Net Profit Margin Profitability N/A 4247.4% Higher Margin IBO
Return on Equity (ROE) Capital Efficiency N/A 71.2% Higher ROE IBO
52-Week Range Position Momentum 19% ($0โ€“$18) 68% ($0โ€“$7) Stronger Trend IBO
Beta / 30D Volatility Risk Regime -5.32ฮฒ ยท 95% Vol -6.75ฮฒ ยท 120% Vol Lower Realized Risk GRML
Unified Institutional Score Composite Signal 56.8 / 100 (HOLD) 36.8 / 100 (SELL) Higher Composite GRML

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full GRML vs IBO Buy Guide
GRML UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live GRML Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
IBO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live IBO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither GRML nor IBO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.